Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Halberd Corporation (HALB)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0232+0.0024 (+11.54%)
At close: 12:57PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0208
Open0.0206
BidN/A x N/A
AskN/A x N/A
Day's Range0.0206 - 0.0268
52 Week Range0.0120 - 0.1090
Volume1,041,134
Avg. Volume3,448,574
Market Cap1.563M
Beta (5Y Monthly)-7.94
PE Ratio (TTM)7.73
EPS (TTM)0.0030
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for HALB

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • HALBERD CORP
    Analyst Report: Zimmer Biomet Holdings IncBased in Warsaw, Indiana, Zimmer Biomet is the nation's largest pure-play maker of orthopedic devices. The company designs, develops and manufactures reconstructive orthopedic implants, including joint, dental and spinal implants; sports injury repair and trauma products; and related orthopedic surgical products. Its primary customers include musculoskeletal surgeons, neurosurgeons, oral surgeons, dentists, hospitals, distributors, and, in their capacity as agents, healthcare purchasing organizations or buying groups.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • Newsfile

    Halberd Successfully Eradicates TNF-alpha, Major Contributing Factor to Alzheimer's Disease

    Jackson Center, Pennsylvania--(Newsfile Corp. - November 22, 2021) - Halberd Corporation (OTC Pink: HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Through Halberd's patented extracorporeal process, in combination with its patent-pending laser eradication methodology, TNF-α was eliminated through exposure to tuned laser irradiation. TNF-α is an inflammatory cytokine which has been identified as a major co

  • ACCESSWIRE

    Halberd Successfully Eradicates TNF-a, a Major Contributing Factor to Alzheimer’s Disease

    JACKSON CENTER, PA / ACCESSWIRE / November 22, 2021 / Halberd Corporation (OTC PINK:HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Through Halberd's patented extracorporeal process, in combination with its patent-pending laser eradication methodology, TNF-α was eliminated through exposure to tuned laser irradiation.

  • ACCESSWIRE

    Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves

    JACKSON CENTER, PA / ACCESSWIRE / November 8, 2021 / Halberd Corporation (OTC PINK:HALB) filed a non-provisional patent application for the extracorporeal treatment of Covid-19 through exposure to radio frequency waves. Previously, Halberd filed a provisional patent application on this treatment method.

Advertisement
Advertisement